Search results for " Interquartile range"

showing 7 items of 7 documents

Do ventilatory parameters influence outcome in patients with severe acute respiratory infection? Secondary analysis of an international, multicentre1…

2021

Purpose: To investigate the possible association between ventilatory settings on the first day of invasive mechanical ventilation (IMV) and mortality in patients admitted to the intensive care unit (ICU) with severe acute respiratory infection (SARI). Materials and methods: In this pre-planned sub-study of a prospective, multicentre observational study, 441 patients with SARI who received controlled IMV during the ICU stay were included in the analysis. Results: ICU and hospital mortality rates were 23.1 and 28.1%, respectively. In multivariable analysis, tidal volume and respiratory rate on the first day of IMV were not associated with an increased risk of death; however, higher driving pr…

ARDSSoins intensifs réanimationmedicine.medical_treatmentAirway pressuresPEEP positive end-expiratory pressureCritical Care and Intensive Care Medicinelaw.inventionHypoxemiaCohort StudiesPositive-Pressure RespirationMechanical ventilationSARI severe acute respiratory infectionlawHospital MortalityProspective StudiesIQR interquartile rangesProspective cohort studyRCT randomized controlled trialTidal volumeSOFA Sequential Organ Failure AssessmentSAPS Simplified Acute Physiology ScoreIntensive care unitVCV volume-controlled ventilationHIV human immunodeficiency virusIntensive Care UnitsIC GLOSSARI Intensive Care Global Study on Severe Acute Respiratory Infectionmedicine.symptomCohort studyLOS length of staymedicine.medical_specialtyVt tidal volumeCOPD Chronic obstructive pulmonary diseaseNYHA New York Heart Association.PCV pressure-controlled ventilationArticleInternal medicineICU Intensive Care UnitSIMV Synchronized intermittent mandatory ventilationmedicineTidal VolumeHumansDP driving pressurePEEPARDS acute respiratory distress syndromeMechanical ventilationbusiness.industryOdds ratioPneumoniaPlateau pressuremedicine.diseaseRespiration ArtificialVILI ventilator induced lung injuryCI confidence intervalOR odds ratioIMV invasive mechanical ventilationCPAP continuous positive airway pressureARDSbusinessSD standard deviationECMO extracorporeal membrane oxygenationPBW predicted body weightPplat plateau pressure
researchProduct

Dysfunction of attention switching networks in amyotrophic lateral sclerosis

2019

Objective To localise and characterise changes in cognitive networks in Amyotrophic Lateral Sclerosis (ALS) using source analysis of mismatch negativity (MMN) waveforms. Rationale The MMN waveform has an increased average delay in ALS. MMN has been attributed to change detection and involuntary attention switching. This therefore indicates pathological impairment of the neural network components which generate these functions. Source localisation can mitigate the poor spatial resolution of sensor-level EEG analysis by associating the sensor-level signals to the contributing brain sources. The functional activity in each generating source can therefore be individually measured and investigat…

MaleMismatch negativitySource localisationEEG ElectroencephalographyMismatch negativityNetworkElectroencephalographylcsh:RC346-429PET Positron emission tomographyCognition0302 clinical medicineC9orf72AttentionEEGAUROC Area under receiver operating characteristic curveAmyotrophic lateral sclerosisAged 80 and overmedicine.diagnostic_test05 social sciencesCognitive flexibilityBrainRegular ArticleElectroencephalographyCognitionMiddle AgedSTG Superior temporal gyrusNeurologyMTG Mid temporal gyrusDLPFC Dorsolateral prefrontal cortexlcsh:R858-859.7FemaleLCMV Linearly constrained minimum varianceIFG Inferior frontal gyrusAdultCognitive Neurosciencelcsh:Computer applications to medicine. Medical informatics050105 experimental psychologyCWIT Colour-word interference test03 medical and health sciencesfMRI Functional magnetic resonance imagingMEG MagnetoencephalographymedicineMMN Mismatch negativityHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingLS Amyotrophic Lateral SclerosisAAL Automated Anatomical Labellinglcsh:Neurology. Diseases of the nervous systemAEP Auditory evoked potentialAgedbusiness.industryAmyotrophic Lateral SclerosisIQR Interquartile rangeNeurophysiologyqEEG Quantitative EEGmedicine.diseaseNeurology (clinical)Nerve NetFunctional magnetic resonance imagingbusinessNeuroscience030217 neurology & neurosurgeryeLORETA Exact low-resolution brain electromagnetic tomographyNeuroImage: Clinical
researchProduct

Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases.

2021

Patients with pre-existing respiratory diseases in the setting of COVID-19 may have a greater risk of severe complications and even death.A retrospective, multicenter, cohort study with 5847 COVID-19 patients admitted to hospitals. Patients were separated in two groups, with/without previous lung disease. Evaluation of factors associated with survival and secondary composite end-point such as ICU admission and respiratory support, were explored.1,271 patients (22%) had a previous lung disease, mostly COPD. All-cause mortality occurred in 376 patients with lung disease (29.5%) and in 819 patients without (17.9%) (Previous lung disease is a risk factor for mortality in patients with COVID-19.…

HOPE-COVID-19 Health Outcome Predictive Evaluation for COVID-19Respiratory diseasesOriginal30-Day mortalityenfermedades respiratoriasACE2 angiotensin converting enzyme IIlaw.invention0302 clinical medicineCQ/HCQ chloroquine/hydroxychloroquinelawCOPDrespiratory diseasesPrognosisICU intensive care unitIntensive care unitSTROBE strengthening the reporting of observational studies in epidemiologypronósticomedicine.anatomical_structureEPOCCohort studyPulmonary and Respiratory Medicinemedicine.medical_specialty30-day mortalityRT-PCR real time reverse transcriptase-polymerase chain reactionSARS-CoV-2 severe acute respiratory syndrome coronavirus 2WHO World Health OrganizationMERS middle east respiratory syndrome03 medical and health sciencesInternal medicinemedicineCOPDCOVID-19 2019 novel coronavirusRisk factorIQR interquartile rangeLungmortalidad a 30 díasbusiness.industryFEV1 forced expiratory volume in one secondCOVID-19Retrospective cohort studymedicine.diseaseHR hazard ratioICS inhaled corticosteroidsCI confidence intervalCoronavirusCOPD chronic obstructive pulmonary disease030228 respiratory systemRespiratory failureILD interstitial lung diseaseMiddle East respiratory syndromeprognosisHFNC high flow nasal cannulabusiness
researchProduct

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Hepatocellular carcinomaLCmedicine.medical_treatment:diagnóstico::toma de decisiones clínicas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]NursesRC799-869Liver transplantationCholangiocarcinomaClinical trialsENS-CCAInterquartile rangeDecisió Presa dePandemic:Other subheadings::/diagnosis [Other subheadings]:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]CERO-19Pandèmia de COVID-19 2020-Immunology and AllergyiCCA intrahepatic cholangiocarcinomaCOVID-19 coronavirus disease 2019Liver Cancer Outcome in the COVID-19-pandemic ProjectSettore MED/12 - Gastroenterologiaddc:617IQRGastroenterologyBCLC Barcelona Clinic Liver Cancer:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas [ENFERMEDADES]Diseases of the digestive system. GastroenterologyManagementClinical PracticeClinical trialEuropean Network for the Study of Cholangiocarcinoma:Diagnosis::Clinical Decision-Making [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Fetge - Malalties - DiagnòsticInterquartile rangeLiver cancerLiver cancerPROGRESSION-FREE SURVIVALLiver Cancermedicine.medical_specialtyCoronavirus disease 2019 (COVID-19):Otros calificadores::/diagnóstico [Otros calificadores]610 Medicine & health:Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [DISEASES]LT liver transplantationArticleBarcelona Clinic Liver CancerInternal MedicinemedicineENS-CCA European Network for the Study of CholangiocarcinomaHepatologybusiness.industryCERO-19 Liver Cancer Outcome in the COVID-19-pandemic ProjectCOVID-19IQR Interquartile rangemedicine.diseaseBCLCClinical trialEmergency medicineObservational study610 Medizin und GesundheitbusinessHCC hepatocellular carcinomaLC liver cancerSARS-CoV-2 severe acute respiratory syndrome coronavirus-2
researchProduct

Cardiac Injury in COVID-19–Echoing Prognostication∗

2020

Background Myocardial injury is frequent among patients hospitalized with coronavirus disease-2019 (COVID-19) and is associated with a poor prognosis. However, the mechanisms of myocardial injury remain unclear and prior studies have not reported cardiovascular imaging data. Objectives This study sought to characterize the echocardiographic abnormalities associated with myocardial injury and their prognostic impact in patients with COVID-19. Methods We conducted an international, multicenter cohort study including 7 hospitals in New York City and Milan of hospitalized patients with laboratory-confirmed COVID-19 who had undergone transthoracic echocardiographic (TTE) and electrocardiographic…

Malemyocaardial injuryCoronary AngiographyElectrocardiographyPandemicVentricular Dysfunctionechocardiographymyocardial injuryOriginal Investigationechocardiography; inflammation; myocaardial injury; SARS-CoV-2; troponin; COVID-19COVID-19 coronavirus disease-2019biologyViral EpidemiologytroponinHeartMiddle AgedRV right ventriclemyocardial infarctionItalyTTE transthoracic echocardiographyFemaleCardiology and Cardiovascular MedicineCoronavirus InfectionsEditorial Comment2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAKI acute kidney injuryECG electrocardiographyBetacoronavirusmedicineHumansPandemicsARDS acute respiratory distress syndromeIQR interquartile rangeAgedRetrospective Studiesbusiness.industrySARS-CoV-2MyocardiumCOVID-19medicine.diseasebiology.organism_classificationVirologyCOVID-19 Drug TreatmentCI confidence intervalOR odds ratioPneumoniaLV left ventricleinflammationACS acute coronary syndromeNew York CitybusinessCoronavirus InfectionsBetacoronavirusBiomarkersJournal of the American College of Cardiology
researchProduct

Vasoactive peptide urotensin II in plasma is associated with cerebral vasospasm after aneurysmal subarachnoid hemorrhage and constitutes a potential …

2019

National audience; OBJECTIVECerebral vasospasm (VS) is a severe complication of aneurysmal subarachnoid hemorrhage (SAH). Urotensin II (UII) is a potent vasoactive peptide activating the urotensin (UT) receptor, potentially involved in brain vascular pathologies. The authors hypothesized that UII/UT system antagonism with the UT receptor antagonist/biased ligand urantide may be associated with post-SAH VS. The objectives of this study were 2-fold: 1) to leverage an experimental mouse model of SAH with VS in order to study the effect of urotensinergic system antagonism on neurological outcome, and 2) to investigate the association between plasma UII level and symptomatic VS after SAH in huma…

SAPS II = Simplified Acute Physiology Score IIMCA = middle cerebral arteryAUC = area under the curvesubarachnoid hemorrhage[SDV]Life Sciences [q-bio]ICU = intensive care unitUT = urotensin (receptor)vascular disordersintensive care unitUII = urotensin IIcardiovascular diseaseshumanmouseWFNS = World Federation of Neurosurgical SocietiesEVD = external ventricular drainageACA = anterior cerebral arteryurotensin IInervous system diseasesSAH = subarachnoid hemorrhageSE = standard errorROC = receiver operating characteristic[SDV] Life Sciences [q-bio]cerebral vasospasmVS = vasospasmDCI = delayed cerebral ischemiaCSF = cerebrospinal fluidIRB = institutional review boardmRS = modified Rankin ScaleIQR = interquartile range
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct